| Document |
Document Title |
|
JP2008509931A |
The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprisi...
|
|
JP4070407B2 |
This invention is directed to a process for preparing ±,²-unsaturated alkenoate resin compounds.
|
|
JP2008069158A |
To provide an effective terminal differentiation inducer comprising a pharmacologically acceptable carrier and a therapeutically acceptable amount of the compound described below, and a method of using the same.The novel and active termi...
|
|
JP2008069163A |
To provide a method for synthesizing each of aldehydes, ketones, oximes, amines and hydroxamic acid compounds.Provided is a solid-phase synthesis method for each of aldehydes, ketones, oximes, amines and hydroxamic acid compounds. A poly...
|
|
JP2008508348A |
This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammator...
|
|
JP4060359B2 |
PCT No. PCT/EP96/04446 Sec. 371 Date Apr. 15, 1998 Sec. 102(e) Date Apr. 15, 1998 PCT Filed Oct. 11, 1996 PCT Pub. No. WO97/15552 PCT Pub. Date May 1, 1997Phenylacetic acid derivatives of the formula I where the substituents and the inde...
|
|
JP2008050361A |
To provide pharmaceuticals in treating or preventing a disease or condition in which cannobinoid receptor activation plays a role.The present invention relates to naphthalene derivatives of formula (I), wherein X is S, S(O), S(O)2, S(O)2...
|
|
JP2008506776A |
This invention relates to iminodiacetic acid and diamine hydroxamic acid derivatives, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example ca...
|
|
JP4055993B2 |
Compound of formula (I), wherein X is C1-6 alkylene or C2-6 alkenylene, each of which is optionally substituted by one or more flluorine atoms; R is aryl or C3-8 cycloalkyl optionally substituted by one or more fluorine atoms; W is N or ...
|
|
JP2008505879A |
Disclosed are materials and methods for preparing optically active beta-amino acids of Formula 1, which bind to the alpha-2-delta (alpha2delta) subunit of a calcium channel.
|
|
JP2008505969A |
The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, th...
|
|
JP4053597B2 |
Compounds of the formula:
|
|
JP2006519772T5 |
|
|
JP4045099B2 |
The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors...
|
|
JP2008500270A |
The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances o...
|
|
JPWO2005073180A1 |
To provide a novel compound having an inhibition of AGE production and an AGE production inhibitor containing the compound. (Solution) A compound represented by the following formula, a salt which is acceptable as a drug thereof, a pharm...
|
|
JP2007536328A |
The invention provides highly functionalised spiro-fused lactams of en formula (I) having a cyclohexane moiety with the desired number of protected or un-protected functional groups or carbonated structures, which are introduced with hig...
|
|
JP4020290B2 |
|
|
JP4012819B2 |
The present invention provides hydroxamate compounds of formula I: which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
|
|
JP4012679B2 |
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
JP2007291110A |
To provide a new compound selectively inducing terminal differentiation of tumorous cells. The compound is represented by formula (I) (wherein, R1and R2are each a cycloalkylamino, a pyridineamino, a piperidino, a 9-purine-6-amine or a th...
|
|
JP2007269732A |
To provide a method by which bishydroxamic acid can simply and industrially be produced. The method for producing the bishydroxamic acid represented by formula (I) (wherein, Rs represent each a substituted or an unsubstituted lower alkyl...
|
|
JP3984294B2 |
PCT No. PCT/GB97/01729 Sec. 371 Date Jan. 6, 1999 Sec. 102(e) Date Jan. 6, 1999 PCT Filed Jun. 27, 1997 PCT Pub. No. WO98/04520 PCT Pub. Date Feb. 5, 1998A fungicidal compound of formula (I): or a stereoisomer thereof, wherein A is CH or...
|
|
JP3966623B2 |
To produce an N-alkyl-α-dialkylaminoacetohydroxamic acid compound useful as a deacylation agent, or the like, in high yield by a process necessitating short reaction time and forming suppressed amount of by-product by carrying out the r...
|
|
JP3964613B2 |
To obtain a carrier compound and a composition effective for delivering an activator and to provide an administration method including an oral administration and a preparation method. This composition contains (A) at least one activator ...
|
|
JP2007523087A |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
|
|
JP2007521237A |
Novel amidine and diamidine compounds are useful in the treatment of microbial infections, including mycobacterial, fungal and protozoal infections. Pharmaceutical formulations comprising these compounds can be used in methods of treatin...
|
|
JP3950046B2 |
The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
|
|
JP2007518786A |
The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising adm...
|
|
JP3935199B2 |
The present invention relates to novel 5-HT4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C1-4)alkyloxy or phenyl(C1-4)al...
|
|
JP3927772B2 |
The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.
|
|
JP2007513958A |
Processes for preparing 10-amino-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-
a]azepine-2-carboxylates and related compounds are disclosed. The preparation of carboxamide derivatives from these carboxylates is also disclosed. The ...
|
|
JP3922431B2 |
A compound of formula (I)wherein:R isopropyl;n is 0;R<1 >is naphthylmethyl;R<2 >is t-butyl; andR<3 >is methyl;is useful in the treatment of disorders mediated by s-CD23.
|
|
JP2007513098A |
The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R1, A, R9, X, B, R8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one...
|
|
JP2007512367A |
The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit hist...
|
|
JP2007509858A |
The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using th...
|
|
JP2007509171A |
The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid L...
|
|
JP2007509125A |
This invention provides a novel polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iod
o-phenylamino)-benzamide, as well a pharmaceutical compositions and therapeutic methods utilizing the polymorphic form.
|
|
JP2007508349A |
The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic compos...
|
|
JP2007077170A |
To provide a technique of a simple and inexpensive system by which activators in a wide range can be delivered and which can be prepared easily.The modified amino acid compound useful in the delivery of an active agent is provided. The a...
|
|
JP2007505860A |
The invention relates to a method of preventing or treating proliferative diseases such as cancer in a mammal, particularly a human, with a combination of pharmaceutical agents which comprises: (a) an HDAI; and (b) a death receptor ligan...
|
|
JP2007505044A |
Many metal chelators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyamine-metal chelator conjugates of the invention are compounds comprising a first moiety which is a metal ...
|
|
JP3883566B2 |
Carbamates of the formula I wherein B is a saturated or unsaturated heterocyclic group, and the other substituents are defined in the specification, and having crop protection properties.
|
|
JP2007502838A |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
JP3881692B2 |
The present invention relates to benzamidoxime derivatives represented by the formula ÄIÜ; wherein R<1> is unsubstituted or substituted C1 - C4 alkyl, unsubstituted or substituted C2 - C4 alkenyl or unsubstituted or substituted C2 - C4...
|
|
JP3877762B2 |
PCT No. PCT/HU95/00014 Sec. 371 Date Nov. 5, 1996 Sec. 102(e) Date Nov. 5, 1996 PCT Filed May 4, 1995 PCT Pub. No. WO95/30649 PCT Pub. Date Nov. 16, 1995Hydroximic acid derivatives possess anti-ischemic effects, and therefore, they are u...
|
|
JP2006348034A |
To provide a method for producing a MEK(mitogen-activated protein kinase extracellular regulated kinase) inhibitor, N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iod
o-phenylamino)benzamide, useful for treating diseases mediat...
|
|
JP3857333B2 |
PURPOSE: To obtain the subject material improved in shelf life of a latent image without adversely affecting the shelf life of emulsions and various photographic properties by forming a photosensitive silver halide emulsion layer contain...
|
|
JP2006525973A |
The present invention relates to novel bioisosteres of the antibiotic actinonin of the general formula (I). The novel compounds are of particular interest as inhibitors of metalloproteinases.
|
|
JP3842132B2 |
N-(4-carbamimidoyl-phenyl)-glycine derivatives have the formula:wherein X and R1 to R5 are as defined herein, and includes hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters ther...
|
